Given that Aβ deposition and tau hyperphosphorylation are key pathological hallmarks of AD, we examined whether BYHWD ameliorates these pathologies via modulation of the C/EBPβ/AEP signaling pathway. The gene discussed is MAPT; the disease is Alzheimer disease.